Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

Abstract Background Controversy exists for the use of Ki67 protein expression as a predictive marker to select patients who do or do not derive benefit from adjuvant endocrine therapy. Whether other proliferation markers, like Cyclin D1, and mitotic count can also be used to identify those estrogen...

Full description

Bibliographic Details
Main Authors: Karin Beelen, Mark Opdam, Tesa Severson, Rutger Koornstra, Andrew Vincent, Jelle Wesseling, Joyce Sanders, Jan Vermorken, Paul van Diest, Sabine Linn
Format: Article
Language:English
Published: BMC 2018-07-01
Series:BMC Cancer
Subjects:
Breast cancer
Tamoxifen
Cell proliferation
Ki67
Mitotic count
Online Access:http://link.springer.com/article/10.1186/s12885-018-4516-1

Internet

http://link.springer.com/article/10.1186/s12885-018-4516-1

Similar Items